Список литературы к Главе 12

1. Никитин Е.А., Халлек M., Байков В.В., Бакиров Б.А., Бессмельцев С.С., Загоскина Т.П. и др. Российские клинические рекомендации по диагностике и лечению хронического лимфолейкоза (версия 2012 г) // Современная онкология. 2012. № 4. С. 10–14.

2. Galton D.A. et al. The use of chlorambucil and steroids in the treatment of chronic lymphocytic leukaemia // Br. J. Haematol. 1961. Vol. 7. P. 73–98.

3. Кассирский И.А., Волкова М.А. Основные проблемы хронического лимфолейкоза // Терапевтический архив. 1970. Т. 42, № 1. С. 8–15.

4. Бессмельцев С.С., Бялик Т.Е., Волкова М.А., Голубева М.Е., Загоскина Т.П., Зарицкий А.Ю. и др. Рекомендации по обследованию и лечению больных В­клеточным хроническим лимфолейкозом // Современная онкология. 2008. Т. 10, № 4. С. 10–22.

5. Effectiveness of «CHOP» regimen in advanced untreated chronic lymphocytic leukaemia. French Cooperative Group on Chronic Lymphocytic Leukaemia // Lancet. 1986. Vol. 1, N 8494. P. 1346–1349.

6. CHOP regimen versus intermittent chlorambucil­prednisone in stage B chronic lymphocytic leukemia. Short term results from a randomized clinical trial. French Cooperative Group on Chronic Lymphocytic Leukemia // Nouv. Rev. Fr. Hematol. 1988. Vol. 30, N 5–6. P. 449–452.

7. Long­term results of the CHOP regimen in stage C chronic lymphocytic leukaemia. French Cooperative Group on Chronic Lymphocytic Leukaemia // Br. J. Haematol. 1989. Vol. 73, N 3. P. 334–340.

8. A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. The French Cooperative Group on Chronic Lymphocytic Leukemia // Blood. 1990. Vol. 75, N 7. P. 1422–1425.

9. Leblond V. et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide­doxorubicin­prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease // Blood. 2001. Vol. 98, N 9. P. 2640–2644.

10. Kimby E. et al. A systematic overview of chemotherapy effects in B­cell chronic lymphocytic leukaemia // Acta Oncol. 2001. Vol. 40, N 2–3. P. 224–230.

11. Langerbeins P. et al. Poor efficacy and tolerability of R­CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation // Am. J. Hematol. 2014. Vol. 89, N 12. P. E239–E243.

12. Cramer P. et al. Second­line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group // Leuk. Lymphoma. 2013. Vol. 54, N 8. P. 1821–1822.

13. Keating M.J. et al. Fludarabine phosphate: a new active agent in hematologic malignancies // Semin. Hematol. 1994. Vol. 31, N 1. P. 28–39.

14. Keating M.J. et al. The expanding role of fludarabine in hematologic malignancies // Leuk. Lymphoma. 1994. Vol. 14, suppl. 2. P. 11–16.

15. Keating M.J. et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia // J. Clin. Oncol. 2005. Vol. 23, N 18. P. 4079–4088.

16. Rai K.R. et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia // N. Engl. J. Med. 2000. Vol. 343, N 24. P. 1750–1757.

17. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia // Semin. Oncol. 1993. Vol. 20, N 5, suppl. 7. P. 21–23.

18. Hallek M., Eichhorst B.F. Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia // Hematol. J. 2004. Vol. 5, suppl. 1. P. S20–S30.

19. Bosch F. et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia // Br. J. Haematol. 2002. Vol. 119, N 4. P. 976–984.

20. Hendry L. et al. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non­Hodgkin's lymphoma // Leuk. Lymphoma. 2004. Vol. 45, N 5. P. 945–950.

21. Catovsky D. et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial // Lancet. 2007. Vol. 370, N 9583. P. 230–239.

22. Eichhorst B.F. et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first­line therapy of younger patients with chronic lymphocytic leukemia // Blood. 2006. Vol. 107, N 3. P. 885–891.

23. Flinn I.W. et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997 // J. Clin. Oncol. 2007. Vol. 25, N 7. P. 793–798.

24. Bellosillo B. et al. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B­cell chronic lymphocytic leukemia // Blood. 1999. Vol. 94, N 8. P. 2836–2843.

25. Eichhorst B.F. et al. First­line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia // Blood. 2009. Vol. 114, N 16. P. 3382–3391.

26. Ozegowski W., Krebs D. IMET 3393,(­[1­Methyl­5­(b­bis­chloroethyl)­amino­benzimidazolyl­(2)]­butyric acid hydrochloride, a new cytostatic agent from among the series of benzimidazole mustard compounds // Zbl. Pharm. 1971. Vol. 110. P. 1013–1019.

27. Knauf W.U. et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia // J. Clin. Oncol. 2009. Vol. 27, N 26. P. 4378–4384.